GVP Module XV: Safety Communication

Introduction

Safety communication is the part of the pharmacovigilance system through which relevant safety information is conveyed to the people and organisations who may need to understand or act on it. It therefore connects scientific assessment with clinical and regulatory practice.

Communication is not simply the publication of a safety message. The organisation must determine what is known, what remains uncertain, who needs the information, what action is expected and which communication channel is appropriate. The same safety issue may require different communication for regulators, healthcare professionals, patients, investigators or internal decision-makers.

The quality of safety communication consequently depends on the quality of the underlying assessment and on the organisation's ability to translate that assessment without distorting its meaning.

1. Purpose of Safety Communication

The purpose of safety communication is to ensure that relevant information about the safe and effective use of medicinal products reaches appropriate audiences in a timely and understandable form.

The objective is not simply to increase awareness. A communication should support an appropriate response to the safety information, whether that means recognising a potential adverse reaction, changing prescribing or monitoring behaviour, understanding uncertainty or continuing appropriate treatment.

Communication is therefore an intervention within the pharmacovigilance system and should be governed accordingly.

2. Communication Is Part of Pharmacovigilance

Safety communication sits within the wider pharmacovigilance system rather than operating as an independent public-relations activity.

Signals, aggregate evaluations, risk-management activities and regulatory decisions can all generate communication needs. Conversely, communication can influence reporting behaviour and clinical use, creating information that feeds back into pharmacovigilance.

This two-way relationship means that communication activities should be connected to the relevant safety processes and records.

3. Regulatory Framework

GVP Module XV provides the EU pharmacovigilance framework for safety communication. It should be read alongside the applicable provisions of EU pharmaceutical legislation, risk-management requirements and EMA or competent-authority procedures relevant to the particular communication.

The regulatory framework distinguishes different communication responsibilities and channels. An MAH may have obligations to communicate safety information, while national competent authorities, EMA and the European Commission have their own roles within the EU regulatory network.

The organisation should therefore distinguish a legal or regulatory communication requirement from an operational communication practice adopted to support it.

4. The Communication Question Comes After the Safety Question

A communication should not be drafted before the underlying safety issue is sufficiently understood for the purpose of the communication.

The assessment should establish the relevant evidence, clinical significance, uncertainty and required action. The communication then translates that conclusion for the intended audience.

This sequence is important because communication should not become a substitute for scientific assessment. If the evidence is preliminary, the message should communicate that uncertainty rather than creating false certainty through simplified wording.

5. Identify the Audience

Different audiences need different information.

Regulators may require detailed scientific and regulatory reasoning. Healthcare professionals generally need clinically actionable information, including what has changed and what they should do. Patients may need clear information about symptoms, risks, benefits and when to seek medical advice.

Internal pharmacovigilance and regulatory teams may need still more detailed information to implement the resulting controls.

The audience therefore determines the level, format and terminology of the communication without changing the underlying scientific conclusion.

6. Patients and Healthcare Professionals

Communication intended for patients and healthcare professionals should be understandable without sacrificing accuracy.

For healthcare professionals, the practical implications may include recognition of a newly characterised adverse reaction, changes in monitoring or prescribing, or advice concerning a specific population.

For patients, the communication may need to explain what the risk means in practical terms and what action, if any, should be taken. Patient communication should avoid language that could encourage inappropriate discontinuation of treatment where continued therapy may be important.

7. Regulators and the Scientific Record

Regulatory communication generally requires a level of detail sufficient for independent assessment of the safety issue and the proposed or completed action.

The organisation should preserve the underlying scientific evidence and reasoning supporting the communication. A public message may necessarily be shorter than the internal assessment, but the shortened message should remain faithful to the evidence.

This creates an important distinction between communication brevity and scientific simplification. A message can be concise without becoming inaccurate.

8. Internal Communication

Internal communication ensures that relevant functions understand an emerging safety issue and their responsibilities.

Important signals may require communication between pharmacovigilance, medical, regulatory affairs, quality, clinical, supply and other functions. The communication should identify the decision required and the owner of any resulting action.

Internal communication should therefore be integrated with controlled action tracking rather than existing only as informal correspondence.

9. Choosing the Appropriate Channel

The channel should be selected according to the urgency, audience, complexity and required action.

Possible channels include product information, direct communications to healthcare professionals, public safety information, regulatory publications, websites, patient-facing materials, scientific publications and internal controlled communications.

The existence of multiple channels creates a consistency requirement. The organisation should be able to explain why a particular channel was selected and how related communications are coordinated.

10. Direct Healthcare-Professional Communication

A direct healthcare-professional communication can be appropriate when healthcare professionals need important information about a safety issue and specific action is required or recommended.

Such communication is not simply an alternative form of advertising or general awareness material. Its purpose is to convey safety information and, where applicable, the action required to reduce risk.

The content, distribution and regulatory process should follow the applicable EU and national requirements.

11. Product Information as a Safety Communication Tool

The product information is one of the principal controlled channels for communicating established information about the safe and effective use of a medicinal product.

A safety signal may therefore lead to assessment of whether the product information adequately reflects the current evidence. However, signal detection itself does not automatically determine that a variation is required.

The scientific conclusion, regulatory assessment and applicable product-information process must be considered together.

12. Timing

The appropriate timing of communication depends on the nature of the safety issue, the urgency of the risk and the applicable regulatory requirements.

Communication should not be delayed merely to achieve perfect scientific certainty when timely action is needed to protect patients. At the same time, premature communication of an unsubstantiated hypothesis can create confusion or unnecessary concern.

The organisation should therefore document the reasoning behind significant timing decisions.

13. Communicating Uncertainty

Scientific uncertainty should be communicated explicitly when it is relevant to understanding the safety issue.

Useful uncertainty statements distinguish what has been observed from what has been established. They can explain limitations in the evidence, the reason further investigation is continuing and what action should be taken in the meantime.

Avoiding uncertainty in order to make a message simpler can make the communication scientifically misleading.

14. Proportionality

The intensity of communication should be proportionate to the significance of the safety issue.

A serious emerging risk may require rapid and prominent communication. A minor change in understanding may be better addressed through routine controlled channels.

Proportionality should consider seriousness, frequency, preventability, affected population, uncertainty and the potential consequences of misunderstanding the message.

15. Consistency Across Communications

The same safety issue may appear in several communication channels over time.

The wording does not need to be identical in every channel, because audiences have different needs. The underlying facts, level of certainty and essential recommendations should nevertheless remain consistent.

Differences in wording should therefore result from audience adaptation rather than contradictory scientific positions.

16. Communication and Risk Management

Safety communication can be part of a broader risk-minimisation strategy.

Where communication is intended to influence prescribing, monitoring, administration or patient behaviour, the intended objective should be defined. This makes it possible to assess later whether the communication achieved its purpose.

Communication should therefore be considered within the RMP where it forms part of risk-minimisation or additional pharmacovigilance activity.

17. Communication and Signal Management

Signal management and safety communication are connected but distinct processes.

A signal may require internal escalation without requiring immediate public communication. Conversely, an established risk may require communication even though no new signal is being assessed.

The communication decision should therefore follow the nature and significance of the safety issue rather than the mere existence of a signal status.

18. Communication and Aggregate Safety Evaluation

PSURs and other aggregate evaluations may identify changes in the safety profile that create communication needs.

Conversely, safety communications can alter reporting behaviour and clinical use, which may influence subsequent aggregate analyses. The organisation should therefore retain awareness of communication events when interpreting changes in safety data.

This is another example of why pharmacovigilance processes should not operate as isolated workflows.

19. Communication Governance

A controlled communication process should define responsibilities for scientific content, medical review, regulatory assessment, approval, distribution and record retention.

The appropriate governance model will vary by organisation and communication type. What matters is that significant safety communications are subject to sufficient review before release and that the responsible decision-makers are identifiable.

Governance should facilitate timely communication rather than create unnecessary approval layers.

20. A Communication Lifecycle

Safety communication can be understood as a controlled lifecycle:

Safety information
      ↓
Scientific assessment
      ↓
Communication need
      ↓
Audience and objective
      ↓
Channel and timing
      ↓
Content development
      ↓
Scientific / regulatory review
      ↓
Communication
      ↓
Implementation
      ↓
Effectiveness assessment
      ↓
Reassessment

This model makes clear that publication is not the end of the process. Where communication is intended to change behaviour or reduce risk, implementation and effectiveness matter as much as drafting.

21. Communication for Emerging Safety Concerns

Emerging safety concerns require particular discipline because the evidence may continue to change while communication is being prepared.

The message should distinguish the observation, the current assessment and the action being taken. If the evidence is preliminary, the communication should not imply that causality has been established simply because the issue is considered sufficiently important to communicate.

A rapidly evolving issue may require updates as the scientific assessment develops. Version control and clear dating are therefore important parts of the communication process.

22. Communication During Regulatory Assessment

Safety information may be communicated while a regulatory assessment is still underway.

In such circumstances, the organisation should distinguish the existence of a regulatory review from the conclusion of that review. A regulatory assessment may consider several possible outcomes, and communication should not prematurely represent a proposal or question as a final regulatory decision.

This distinction is particularly important where public attention is high.

23. Urgent Safety Communication

An urgent communication pathway should be available for situations in which delay could materially affect patient safety.

The pathway should establish who can initiate the process, which functions must be involved, how scientific and regulatory review is performed under time pressure and how the communication is distributed.

Urgency should accelerate the controlled process rather than bypassing it altogether.

24. Communication After a Regulatory Decision

When a regulatory authority reaches a safety decision, the MAH may need to implement associated communication and product-information changes.

The organisation should ensure that the approved regulatory position is accurately reflected in downstream materials and that relevant functions receive the final information needed for implementation.

A communication should not continue to describe a provisional assessment after the regulatory position has materially changed.

25. Communication Across Member States

The EU regulatory system operates across Member States with different healthcare systems, languages and national implementation arrangements.

A safety communication may therefore require coordination between centrally developed scientific content and national implementation.

The organisation should maintain the scientific consistency of the message while allowing the appropriate national format and procedural requirements to be applied.

26. Language and Translation

Translation is a scientific and regulatory control, not merely a linguistic exercise.

A translated safety message should preserve the meaning, degree of certainty and intended action of the approved source communication. Material ambiguity introduced during translation can change the clinical meaning of the message.

Where safety information is particularly sensitive, appropriate review of translated content should be built into the process.

27. Patient-Centred Communication

Patient communication should begin with the patient's practical information needs.

A technically accurate description may still fail if patients cannot understand what the risk means for them, what symptoms matter or what action is appropriate. The communication should therefore use clear language while retaining the essential scientific limitations.

Patient communication should also avoid implying that a patient should change treatment independently when professional advice is required.

28. Healthcare-Professional Communication

Healthcare professionals generally need sufficient information to recognise the safety issue and apply the recommended action in clinical practice.

The communication should identify the affected product, the relevant risk, the population or circumstances involved, the evidence supporting the change and the action required.

Where the recommendation is conditional or the evidence remains uncertain, those qualifications should be retained.

29. Communication and Behaviour Change

If the purpose of a communication is to change clinical behaviour, the desired behaviour should be explicit.

For example, a message may aim to increase monitoring, avoid a particular combination, recognise a specific symptom or follow a revised administration procedure.

A communication that provides information without making the intended action clear may have limited risk-management value.

30. Communication Effectiveness

Effectiveness should be assessed according to the objective of the communication.

Possible evidence may include awareness surveys, prescribing or utilisation data, reporting patterns, monitoring of implementation, targeted follow-up or other appropriate measures. The method should reflect the communication objective and the degree to which behaviour is expected to change.

High distribution volume does not demonstrate effectiveness by itself.

31. Communication Can Affect the Safety Data

A communication can change reporting behaviour, prescribing patterns and clinical attention.

An increase in reports after a safety communication may therefore reflect increased awareness rather than increased incidence. Similarly, a reduction in exposure may change the absolute number of reports without demonstrating that the underlying risk has changed.

Signal assessment should take relevant communication events into account when interpreting subsequent data.

32. Communication and Media Interest

Media attention can increase the speed at which safety information reaches the public, but media coverage is not itself a substitute for controlled safety communication.

Organisations should ensure that public statements remain consistent with the scientific and regulatory position. Where media reporting contains inaccuracies, the appropriate response should be determined according to the potential impact and the available communication channels.

The objective is to maintain an accurate safety message rather than to respond to every media statement.

33. Social Media and Digital Channels

Digital channels can make safety information rapidly accessible but also create challenges around context, permanence, audience diversity and rapid redistribution.

Where organisations use digital channels for safety communication, governance should address approval, monitoring, version control and escalation of material questions or misinformation.

A short digital message should still be traceable to the controlled scientific content from which it was derived.

34. Communication With the Scientific Community

Scientific publications and presentations can contribute to transparent dissemination of safety information and facilitate scientific discussion.

They should distinguish established findings from hypotheses and describe important limitations. Publication does not remove the organisation's other regulatory or pharmacovigilance communication responsibilities.

Scientific communication should therefore complement, rather than replace, the appropriate regulatory communication pathway.

35. Communication Following Product Quality Issues

Where a safety concern is linked to product quality, communication may need coordination between pharmacovigilance, quality and regulatory functions.

The message should accurately describe the affected product or batch, the known or suspected issue, the potential patient implications and the action required, subject to the applicable regulatory process.

Quality and safety communications should not provide conflicting explanations of the same event.

36. Communication Following Medication Errors

Medication-error communications may need to address how the error occurs and how it can be prevented.

The message may therefore concern packaging, preparation, administration, dosing, device use or instructions rather than an intrinsic adverse reaction.

The intended preventive action should be explicit, and any subsequent effectiveness assessment should examine whether the communication reduced the targeted error or improved correct use.

37. Communication and Risk-Minimisation Materials

Some safety communications form part of specific risk-minimisation measures.

Where this occurs, the communication should be linked to the relevant RMP objective and implementation process. The organisation should know which population is being reached, what behaviour is intended to change and how effectiveness will be evaluated when required.

This connection prevents communication from becoming a standalone activity with no defined risk-management purpose.

38. Communication Records

The organisation should retain records sufficient to reconstruct significant safety communications.

Depending on the communication, these may include the initiating safety assessment, decision rationale, approved content, review and approval records, distribution evidence, implementation records, regulatory correspondence and effectiveness results.

Record retention should support both operational follow-up and later inspection or scientific review.

39. Version Control

Safety communication can become misleading when different versions circulate simultaneously.

Controlled versioning should identify the current approved content and, where relevant, the relationship between an updated message and the previous version.

This is especially important when the scientific assessment changes rapidly or when multiple Member States and channels are involved.

40. Communication Deviations

Failures in distribution, translation, approval, timing or content should be assessed according to their potential effect on patient safety and regulatory compliance.

The investigation should determine whether the failure was isolated or indicates a weakness in the communication system.

Where corrective action is required, the organisation should address the underlying process rather than simply resend the message.

41. Illustrative Inspection Scenario: The Message Does Not Match the Assessment

The final safety assessment describes an association as uncertain, while the public communication states that the product "causes" the event.

The potential weakness is a loss of scientific qualification during translation from the assessment to the communication.

A controlled review process should ensure that simplification does not alter the scientific conclusion.

42. Illustrative Inspection Scenario: Distribution Is Recorded, Understanding Is Not

The organisation can demonstrate that a healthcare-professional communication was sent to the intended recipients but has no evidence addressing whether the intended safety message was understood or acted upon where effectiveness assessment was required.

Distribution demonstrates delivery. It does not necessarily demonstrate effectiveness.

43. Illustrative Inspection Scenario: Conflicting Versions Remain in Circulation

A revised safety message has been issued, but an obsolete version remains available through an uncontrolled digital channel.

The potential weakness is inadequate version and channel control. The organisation should have a process for identifying and managing obsolete communications where continued availability could cause misunderstanding.

44. Communication Governance Model

A mature safety-communication system can be represented as:

Safety evidence
      ↓
Scientific conclusion
      ↓
Communication need
      ↓
Audience + objective
      ↓
Channel + timing
      ↓
Controlled content
      ↓
Scientific / regulatory review
      ↓
Distribution
      ↓
Implementation
      ↓
Effectiveness
      ↓
Update / reassessment

The important control is the connection between each stage. Communication should remain anchored to the evidence and should feed information about implementation and effectiveness back into the pharmacovigilance system.

45. Governance of Significant Communications

The more consequential the safety issue, the more important it is that the communication process has clear accountability.

The organisation should be able to identify who owns the underlying safety assessment, who decides that communication is required, who approves the scientific content, who coordinates regulatory requirements and who verifies implementation.

These roles may be distributed across functions, but responsibility should remain traceable.

46. The QPPV and Safety Communication

The QPPV does not need to approve every routine communication. The appropriate level of QPPV involvement depends on the significance of the safety issue and the applicable organisational governance model.

For significant emerging risks, the QPPV should have sufficient visibility to understand the safety issue, the communication decision and its implications for the pharmacovigilance system.

The QPPV's role is therefore one of appropriate oversight rather than routine editorial ownership.

47. MAH Responsibility

The MAH remains responsible for ensuring that its pharmacovigilance system can identify and communicate relevant safety information appropriately.

Activities may be delegated to affiliates, vendors or specialist communication functions, but delegation does not remove the need for effective oversight and controlled interfaces.

The organisation should therefore know how a safety communication initiated outside the central pharmacovigilance function enters the controlled system and how the resulting actions are tracked.

48. Vendor and Affiliate Controls

External agencies may support drafting, translation, distribution or monitoring. The MAH should nevertheless retain appropriate control over scientific content, regulatory requirements, approval and records.

Agreements and procedures should define responsibilities, escalation routes and access to information needed to investigate communication failures or assess effectiveness.

49. Communication During Product Transitions

Changes in manufacturing, ownership, distribution arrangements or marketing authorisation status can create communication risks.

The organisation should ensure that responsibility for active safety communications remains clear during transitions and that relevant historical information is available to the responsible pharmacovigilance organisation.

A change in organisational ownership should not create a gap in safety communication or obscure the history of previous messages.

50. Communication and Benefit-Risk Assessment

Safety communication should be interpreted within the overall benefit-risk context of the medicinal product.

A safety message should not imply that the presence of a risk means that treatment is generally inappropriate. Where benefits remain important, the communication should explain the risk and the appropriate management approach without unnecessarily undermining appropriate treatment.

The precise balance depends on the evidence, the clinical context and the applicable regulatory position.

51. Avoiding Alarmism

Effective safety communication should neither minimise a genuine concern nor exaggerate uncertain evidence.

Alarmist wording can lead to inappropriate discontinuation, avoidance of useful treatment or distorted public perception. Understated wording can fail to prompt appropriate risk-reducing action.

The appropriate tone follows from the evidence, seriousness and intended action.

52. Avoiding False Reassurance

The opposite problem is communication that provides reassurance beyond what the evidence supports.

Statements such as "there is no risk" are generally inappropriate when the scientific assessment merely indicates that no new evidence of increased risk has been identified.

The communication should distinguish absence of an identified signal from proof that an adverse event cannot occur.

53. Communication and Causality

Safety communication should use causal language carefully.

A report of an adverse event does not establish that the medicinal product caused it. A validated signal indicates a potential new causal association requiring further assessment. A scientific conclusion may support a stronger statement when the evidence justifies it.

Communication should preserve these distinctions rather than collapsing them into a single category of "side effect."

54. Communication and Evidence Hierarchy

Different evidence sources contribute differently to the safety assessment.

A communication may need to describe findings from spontaneous reports, clinical studies, epidemiology or other evidence. The message should not imply a level of certainty that the underlying evidence cannot support.

Where the evidence remains incomplete, communicating what is being done to resolve the uncertainty can help audiences understand why recommendations may change later.

55. Updating a Communication

Safety communication should be capable of evolution.

When new evidence changes the safety assessment, the organisation should determine whether an existing communication remains accurate, requires amendment or should be withdrawn or replaced.

Updates should preserve traceability so that the organisation can explain what changed, why it changed and when the revised message became effective.

56. Effectiveness and the Feedback Loop

The communication lifecycle is incomplete without feedback.

Where a communication has a defined risk-management objective, the organisation should determine whether there is evidence that the intended audience received, understood and acted on the information to the extent relevant to the objective.

The resulting evidence may influence further communication, risk-management measures or the underlying safety assessment.

57. Communication as a Controlled Safety Intervention

The mature model can therefore be expressed as:

Safety concern
      ↓
Evidence assessment
      ↓
Risk / benefit context
      ↓
Communication objective
      ↓
Audience-specific intervention
      ↓
Implementation
      ↓
Behaviour / awareness evidence
      ↓
Effectiveness assessment
      ↓
Further action or reassessment

This model prevents communication from being treated as a one-time publication exercise. Where communication is intended to reduce risk, it functions as a controlled intervention whose performance should be understood.

58. Inspection Perspective

An inspector evaluating safety communication may examine whether important communications can be traced back to the underlying safety assessment and whether the organisation can demonstrate appropriate review, approval, implementation and follow-up.

The inspection question is not simply whether a communication was sent. It is whether the communication system reliably converts relevant safety information into an accurate and proportionate message for the intended audience.

59. Illustrative Inspection Scenario: No Clear Communication Owner

A significant safety issue requires communication, but responsibility is divided between pharmacovigilance, regulatory affairs and corporate communications, with no clearly identified owner.

The potential weakness is an accountability gap. Cross-functional collaboration is appropriate, but a defined owner should coordinate the communication process.

60. Illustrative Inspection Scenario: Communication Is Not Linked to the Safety Record

The organisation can provide the final communication but cannot readily identify the safety assessment and decision that supported it.

The potential weakness is loss of traceability. Significant safety communications should be linked to the evidence and decision record from which they originated.

61. Illustrative Inspection Scenario: Effectiveness Is Assumed

A risk-minimisation communication was distributed successfully, and the organisation concludes that it was effective without defining what behaviour or awareness should have changed.

The potential weakness is confusing delivery with effectiveness. An effectiveness assessment requires a defined objective and appropriate evidence.

62. Practical Review Questions

For a significant safety communication, the organisation should be able to answer:

1. What safety issue triggered the communication?
2. What evidence supported the message?
3. What is known and what remains uncertain?
4. Who is the intended audience?
5. What action or understanding is expected?
6. Why was this channel selected?
7. Why was this timing selected?
8. Who reviewed and approved the content?
9. How was implementation verified?
10. Is effectiveness assessment required?
11. What changed after the communication?
12. When will the communication be reassessed?

These questions provide a practical test of whether communication is functioning as part of the pharmacovigilance system.

Key Takeaways

Safety communication translates pharmacovigilance evidence into information that people can understand and, where necessary, act upon. It is therefore a controlled component of the pharmacovigilance system rather than a separate public-relations activity.

Effective communication preserves the scientific meaning of the underlying assessment while adapting its presentation to the audience. It distinguishes observation from causality, evidence from uncertainty and regulatory decision from preliminary assessment.

Where communication is intended to reduce risk or change behaviour, its lifecycle extends beyond publication to implementation and effectiveness. The mature system therefore connects safety evidence, communication, action and feedback in a continuous loop.

References

1. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module XV — Safety communication.
2. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module I — Pharmacovigilance systems and their quality systems.
3. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module V — Risk management systems.
4. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module IX — Signal Management.
5. Regulation (EC) No 726/2004, as amended.
6. Directive 2001/83/EC, as amended.
7. Commission Implementing Regulation (EU) No 520/2012, as amended.

Regulatory Note

This article explains safety communication within the EU pharmacovigilance framework and distinguishes regulatory requirements from operational governance and recommended practice. Current legislation, GVP guidance and applicable EMA or national competent-authority procedures should be verified when applying the framework to a specific communication.

Inspection scenarios are illustrative and are not presented as documented regulatory findings.